Lifecome Biochemistry Co Ltd Asset Resilience Ratio
Lifecome Biochemistry Co Ltd asset resilience ratio. Lifecome Biochemistry Co Ltd (002868) has an Asset Resilience Ratio of 4.69% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Lifecome Biochemistry Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lifecome Biochemistry Co Ltd (2019–2019)
Asset resilience ratio of Lifecome Biochemistry Co Ltd from 2019 to 2019. This chart shows how Lifecome Biochemistry Co Ltd's Asset Resilience Ratio has changed over time. Read 002868 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lifecome Biochemistry Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Lifecome Biochemistry Co Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥45.35 Million | 4.69% |
| Total Liquid Assets | CN¥45.35 Million | 4.69% |
Asset Resilience Insights
- Limited Liquidity: Lifecome Biochemistry Co Ltd maintains only 4.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lifecome Biochemistry Co Ltd Industry Peers by Asset Resilience Ratio
Compare Lifecome Biochemistry Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Lifecome Biochemistry Co Ltd Asset Resilience Ratio by Year (2019–2019)
Lifecome Biochemistry Co Ltd asset resilience ratio by year from 2019 to 2019. The table below shows the annual Asset Resilience Ratio data for Lifecome Biochemistry Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 17.13% | CN¥173.03 Million ≈ $25.32 Million |
CN¥1.01 Billion ≈ $147.80 Million |
-- |
About Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. engages in research, development, production, and sales of veterinary drugs in China. It offers probiotics and green microbial functional additives; biopesticides, biofertilizers, and pesticide formulations; and food additives. The company was founded in 2003 and is based in Pucheng, China.